ABSTRACT

BACKGROUND
Overactive bladder (OAB) is a chronic, age-related disorder seen in 11% of patients. Symptoms consist of urinary urgency, with or without urinary incontinence, usually with frequency or nocturia. The objective of the present study was to compare the efficacy and side effects of mirabegron and solifenacin as primary therapies in patients with overactive bladder.

METHODS
This was a prospective interventional study. 100 patients aged between 18 years and 50 years with overactive bladder were included and were assigned into two treatment groups of solifenacin 5 mg or mirabegron 50 mg. They were asked to record the number of micturitions in a day, urgency episodes, incontinence episodes and volume of each micturition. All patients went through a basic workup with blood sugar to rule out diabetes, USG KUB to rule out bladder stones, and urine culture and sensitivity to rule out urinary tract infection (UTI).

RESULTS
100 patients with OAB were selected for the study and divided into equal groups, 50 receiving 5 mg solifenacin and 50 receiving 50 mg mirabegron. Both groups increased the mean micturition volume but mirabegron was more effective in increasing the mean micturition in patients with OAB. Both drugs were well tolerated. There was a significant increase in mean micturition volume in mirabegron 50 mg group (by 20.7 + / - 2.2 mL), P < 0.001 whereas in solifenacin group micturition volume was increased to 22.2 + / -0.97 mL). The most common side-effect in the mirabegron group was hypertension and the most common side effect in the solifenacin group was dry mouth.

CONCLUSIONS
Both mirabegron and solifenacin were effective in controlling the frequency of micturition, decreasing urgency and incontinence episodes and increasing the mean volume of micturition. Mirabegron was more effective than solifenacin in controlling urgency and incontinence episodes and increasing the mean volume of micturition.

KEY WORDS
Overactive Bladder (OAB), Micturition, Mirabegron, Solifenacin.
BACKGROUND

Storage symptoms are experienced during the storage phase of the bladder and include any daytime frequency and nocturia. Overactive bladder is a symptomatic condition defined as urgency, with or without urinary incontinence usually with frequency and nocturia. Overactive bladder (OAB) is a chronic, age-related disorder seen in 11.8% of men and 28.7% of women. The prevalence of symptoms of the overactive bladder occurs in women in their late 40’s and men in their 5th decade. The pathophysiology appears to be multifactorial with multiple factors like sensory activity, motor control and reflexes of the lower urinary tract. Two hypotheses have been postulated namely the urothelium based hypothesis and the myogenic hypothesis. In the urothelium based hypothesis, the various mechanical, chemical and inflammatory stimuli alter the sensitivity of cell membrane receptors and cause the release of chemical mediators that trigger bladder contractility. In the myogenic hypothesis there are contractions within the smooth muscle layer of the bladder and propagation to the whole bladder wall. Symptoms consist of urinary urgency, with or without urinary incontinence, usually with frequency or nocturia. Urinary incontinence is present in around 30% of cases and is most bothersome among all symptoms. These patients are evaluated by history and clinical examination to find out any medications or food habits responsible for overactive bladder. They are categorized based on the bladder sensation scale used in the International Consultation On Incontinence Questionnaire bladder diary and patient perception of the intensity of urgency scale. Score ranges from 1 to 5 where.

1. No urgency
2. Mild urgency
3. Moderate urgency
4. Severe urgency and
5. Urgency incontinence.

After the categorization of patients based on scoring systems, they undergo urinalysis, blood sugar, urea, creatinine, urine culture, lower abdomen ultrasound, uroflowmetry and if needed urodynamics in select cases having a high score in urgency scales. An array of management options from behavioural therapy, medical management and surgical management are available. Most patients show good improvement of symptoms on behavioural therapy, dietary modifications and pelvic floor strengthening exercises. Refractory cases that do not respond to antimuscarinic agents has been the mainstay of treatment. Drugs commonly used are antimuscarinics like oxybutynin, solifenacin, flavoxate, tolterodine, hyoscyamine, and darifenacin. As per EAU guidelines for patients with moderate to severe lower urinary tract symptoms, mainly overactive bladder, antimuscarinic agents are strongly recommended and they seem to improve urgency, urinary incontinence and daytime frequency and the level of recommendation in patients with significant post-void residual urine is weak. Mirabegron has similar efficacy but patients remained longer on treatment when compared to antimuscarinics. OAB patients may have a suboptimal response or encounter side-effects such as dry mouth, constipation, and blurred vision resulting from muscarinic receptor blockade and urinary retention when used in men with prostatic enlargement. This might affect the persistence of therapy. Therefore, there is a need for a new treatment option for OAB that is effective and well-tolerated, with a different mechanism of action. Mirabegron belongs to a new class of agents developed for the OAB treatment. It’s a selective β3 - adrenergic receptor agonist. It causes relaxation of the detrusor muscle to increase bladder capacity during the storage phase. It doesn’t impair detrusor contractions during the voiding phase of the micturition cycle. In this study, we compared the efficacy of solifenacin with mirabegron in OAB.

METHODS

This study was conducted at SRM University from August 2018 to September 2019 after obtaining ethical committee approval. This was a prospective non-randomised single-blinded interventional study. Based on previous studies our study population included 100 patients between 18 years and 50 years. The patients were alternately assigned into two treatment groups of solifenacin 5 mg (Group 1, 50 patients) and mirabegron 50 mg (Group 2, 50 patients). They were asked to record the number of micturitions in a day, urgency episodes, incontinence episodes and volume of each micturition. Patients were asked to void each time in a bowl or beaker to measure the volume. All patients went through a basic workup with FBS to rule out diabetes, USG KUB to rule out bladder stones, and urine culture and sensitivity to rule out UTI. The sample size was calculated using the following formula

\[ n = \frac{Z^2 \times s^2}{d^2} \]

Where: \( Z \) = Standardized normal deviation (1.96)
\( s \) = Standard deviation collected from previous published international studies (2.79) \( d \) = clinically expected variable (0.8)

Inclusion Criteria

Male and female patients of 18 years or older with overactive bladder symptoms like frequency, urgency, nocturia, urge incontinence for a month or more were enrolled in the study. At baseline, patients must have experienced an average of 0 or more micturitions per 24 hours and 3 or more urgency episodes with or without incontinence.

Exclusion Criteria

Patients with

1. Stress urinary incontinence which is a prominent symptom that is seen at the screening
2. An indwelling catheter
3. Symptomatic urinary tract infection
4. Chronic inflammation
5. Benign prostatic hyperplasia (BPH)
6. Diabetic cystopathy
7. Previous history of genitourinary tuberculosis (GUTB)
8. Bladder stones
9. Previous pelvic radiation therapy
10. Previous or current malignant disease of the pelvic organs.
Study Protocol
Treatments were administered once daily during a 12 - week, treatment period. Weekly follow-up was done using telephonic conversation. Study visits were scheduled at weeks 4, 8 and 12. Variables included - number of urgency episodes in a day, incontinence episodes in a day, micturitions in a day, voided volume of each micturition, side - effects of each drug. Data collected from the patient during each study visit were analysed. Adverse effects which emerged were recorded throughout the study. A comparison of all the variables and side-effects between the two groups was done at the end of the study.

Statistical Analysis
Appropriate tests were done using SPSS Software V 22. Paired and unpaired T-tests were used to calculate significance.

| Parameter Measured | Drug Administered | Baseline Value | @ Week - 4 | @ Week - 8 | @ Week - 12 |
|---------------------|-------------------|----------------|------------|------------|------------|
|                     |                   | Mean          | SD (+/-)   | Mean       | SD (+/-)   | Mean       | SD (+/-)   |
| Urgencies / day     | Mirabegron        | 3.75          | 1.08       | 1.64       | 1.84       | 1.06       | 1.32       |
|                     | Solifenacin       | 3.92          | 2.59       | 2.64       | 2.07       | 1.88       | 1.48       |
| Incontinences / day | Mirabegron        | 1.4           | 1.39       | 0.58       | 0.76       | 0.42       | 0.64       |
|                     | Solifenacin       | 1.48          | 1.45       | 0.92       | 1.05       | 0.84       | 1.08       |
| Micturitions / day  | Mirabegron        | 12.02         | 3.1        | 8.98       | 1.53       | 8.34       | 1.32       |
|                     | Solifenacin       | 12.98         | 2.44       | 10.29      | 1.75       | 9.04       | 1.4        |
| Average volume of micturition (in mL) | Mirabegron | 145.44        | 36.77      | 160.2      | 40.93      | 166.94     | 41.95      |
|                     | Solifenacin       | 142.52        | 40         | 153.44     | 39.25      | 159.44     | 40.2       |

Table 2. Urinary Parameters at Baseline and during Treatment

| The average volume of micturition at week 12 between both the Groups |
|-----------------------------|-----------------------------|
| Difference                  | - 5.44                      |
| Standard error              | 0.63                        |
| 95 % CI                     | - 6.6908 to - 4.1192        |
| t - statistic               | 8.631                       |
| DF                          | 98                          |
| Significance level          | P < 0.0001                  |

Table 3. The Average Volume of Micturition at Week 12 between Both the Groups

| Side - Effects | Mirabegron Group (N = 50) | Solifenacin Group (N = 50) |
|----------------|---------------------------|---------------------------|
| Number        | %                         | Number                    | %                         |
| HTN            | 5                         | 10                        | 2                         |
| Dry mouth      | 6                         | 7                         | 1                         |
| Throat irritation | 4                    | 3                         | 6                         |
| Headache       | 4                         | 2                         | 4                         |
| Nausea         | 2                         | 4                         | 3                         |
| Dizziness      | 1                         | 2                         | 3                         |
| Total          | 15                        | 30                        | 18                        |

Table 4. Side Effects

There was a significant increase in mean micturition volume in mirabegron 50 mg group (by 20.7 +/- 2.2 mL), P < 0.001 whereas in solifenacin group micturition volume was increased to 22.2 +/- 0.97 mL). So the difference between the two groups is significant (P < 0.0001) in accordance with the unpaired T-test with 98 degrees of freedom at the score of 8.631. The difference value between the two groups is 5.44.

DISCUSSION
The present study evaluated the efficacy of mirabegron and solifenacin in treating symptoms of OAB and compared variables like the number of urgencies, incontinence and micturition episodes per day and the average volume of micturition. Our study included 100 patients, out of which 37 were males and 63 were females. Both the groups were matched in terms of sex distribution with 21 males in the mirabegron group and 16 in the solifenacin group and 29 females in the mirabegron group and 34 in the solifenacin group. Cases were chosen between ages 18 - 50 years. Both groups were matched in terms of age distribution. There were 30 patients aged from 18 to 25 years, 23 patients aged 26 to 30 years, 15 patients aged 31 to 35 years, 19 patients aged 36 to 40 years and 13 patients aged 40 to 50 years. As we can see from this study, the majority of patients suffering from OAB were young and middle age group population.

Urgency - Mirabegron group episodes decreased from an average of 3.76 +/- 3.08 per day at baseline to 1.64 +/- 1.84; at week 8 they were 1.06 +/- 1.32; at week 12 they were 0.68 +/- 0.98.

There were side-effects seen in 14 patients in the mirabegron group, constituting of 28 %, in 16 patients in the solifenacin, constituting 32 %. 1 patient in the mirabegron group had two side effects, nausea and dizziness. 2 patients in the solifenacin group had two side effects each, one had dry mouth and throat irritation, other one had HTN, and headache.

The number of urgencies, incontinence and micturition episodes per day decreased from baseline to week 12 and the average volume of micturition increased from baseline to week 12 in both groups.
Incontinence

Mirabegron Group

Incontinence episodes decreased from an average of 1.40+/ - 1.39 per day at baseline to 0.58+/ - 0.76 per day at week 4 and to 0.42+/ - 0.64 at week 8 and to 0.16+/ - 0.37 per day at week 12 in the mirabegron group. This shows a decreasing trend of incontinence episodes after initiation of therapy. The decrease in the incontinence episodes from baseline to week 12 was significant as evident by the P-value of < 0.001. This shows that mirabegron is effective in controlling the urgency episodes in a patient with OAB. Solifenacin group: Incontinence episodes decreased from an average of 1.48+/ - 1.45 per day at baseline to 0.92+/ - 1.05 at week 4 and to 0.84+/ - 1.08 at week 8 and to 0.68+/ - 0.87 per day at week 12 in the solifenacin group. This shows a decreasing trend of incontinence episodes after initiation of therapy. The decrease in the incontinence episodes from baseline to week 12 was significant as evident by the P-value of < 0.001. Mirabegron Vs Solifenacin: Though incontinence episodes decreased in both the groups, the decrease in the mirabegron group was significantly more compared to the solifenacin group at week 4 (P < 0.0001), week 8 (P = 0.0278) and week 12 (P = 0.0114). So based on our present study, mirabegron is more effective in decreasing the urgency episodes in patients with OAB.

Micturition Volume

Mirabegron Group

Average volume of each micturition increased from an average of 145.44+/ - 36.07 mL per micturition at baseline to 160.22+/ - 40.93 mL at week 4 and to 166.94+/ - 41.95 mL at week 8 and to 173.12+/ - 40.41 mL per day at week 12 in the mirabegron group. This shows an increasing trend of the average volume of each micturition after initiation of therapy. The increase in volume from baseline to week 12 was significant as evident by the P-value of < 0.001. This shows that mirabegron is effective in increasing the average volume of each micturition, thereby increasing the bladder capacity in a patient with OAB. This is in accordance with the Capricon study conducted by Sender Herschorn, Jack Barkin et al. who studied the role of mirabegron for control of OAB symptoms in 426 patients by comparing mirabegron 25 mg and mirabegron 50 mg. There was a significant increase in mean micturition volume in mirabegron 50 mg group (by 20.7+/ - 2.2 mL from 159.3+/ - 2.5 mL), P < 0.001.

Solifenacin Group

Mean micturition volume increased from an average of 142.52+/ - 40 mL per micturition at baseline to 153.44+/ - 39.25 mL at week 4 and 159.44+/ - 40.20 mL at week 8 and to 164.76+/ - 40.97 mL per day at week 12 in the solifenacin group. This shows an increasing trend of average volume of each micturition after initiation of therapy. The increase in volume from baseline to week 12 was significant as evident by the P-value of < 0.001.

Mirabegron Vs Solifenacin

Mirabegron was more effective in increasing the mean micturition in patients with OAB. There were side-effects...
seen in 16 patients in the mirabegron group, constituting 32 %, in 19 patients in the solifenacin, constituting 38 %. The numbers were not large enough to derive any significance. But in our study, the most common side effect in the mirabegron group was hypertension seen in 5 patients. This is in accordance with the Scorpio study conducted by Vik Khul lar, Gerard Amarenc et al. who conducted to determine the efficacy and tolerability of mirabegron in a phase - 3 randomized control trial. Hypertension was the most common side-effect in this study seen in 29 of 429 patients in the mirabegron 50 mg group, constituting 5.9 %. The most common side effect in the solifenacin group was dry mouth seen in 7 patients. This is in accordance with the study by Basra R, Kelleher C. which showed the most common side-effects with solifenacin were dry mouth and constipation. It is observed that the most common side-effect in the mirabegron group was hypertension and the most common side-effect in the solifenacin group was dry mouth.

CONCLUSIONS

Both mirabegron and solifenacin are effective in controlling the frequency of micturition, decreasing urgency and incontinence episodes and increasing the mean volume of micturition. 

Mirabegron is more effective than solifenacin in controlling urgency and incontinence episodes and increasing the mean volume of micturition. There is no statistical difference between the two drugs with regards to a controlling frequency in OAB. Both drugs are well tolerated. Side-effects are seen slightly more with solifenacin. Dry mouth is more common with solifenacin treatment and hypertension with mirabegron.

Data sharing statement provided by the authors is available with the full text of this article at jemds.com.

Financial or other competing interests: None.

Disclosure forms provided by the authors are available with the full text of this article at jemds.com.

REFERENCES

[1] Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78.
[2] Tang DH, Colayco DC, Khala f KM, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int 2014;113(3):484-91.
[3] Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well - being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388-95.
[4] Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiliUTS. BJU Int 2011;108(9):1459-71.
[5] Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm 2014;20(2):130-40.
[6] Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996;179:47-53.
[7] Gormley EA, Lightner DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193(5):1572-80.
[8] Ohtake A, Sato S, Sasamata M, et al. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder - select ive antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci 2010;112(2):135-41.
[9] EAU guidelines on management of non- neurogenic male LUTS 2021.
[10] Kuo HC, Tzu Chi BT. Comparative of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP. Clinical trials. gov; U.S National Library of Medicine 2018:NCT03632772.